Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2007-02-27
2007-02-27
Page, Thurman K. (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C544S366000, C544S295000, C514S254060, C514S253030
Reexamination Certificate
active
10210474
ABSTRACT:
The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.
REFERENCES:
patent: 3406178 (1968-10-01), Crocker et al.
patent: 3472854 (1969-10-01), Archer
patent: 4200641 (1980-04-01), Vandenberk et al.
patent: 4737500 (1988-04-01), Sorg
patent: 4797399 (1989-01-01), Ueda et al.
patent: 4859692 (1989-08-01), Bernstein et al.
patent: 4886803 (1989-12-01), Sueda et al.
patent: 4940793 (1990-07-01), Botre et al.
patent: 4954503 (1990-09-01), Strupczewski et al.
patent: 5036088 (1991-07-01), Kitaura et al.
patent: 5576318 (1996-11-01), Bietti et al.
patent: 5883094 (1999-03-01), Fliri et al.
patent: 6281218 (2001-08-01), Cereda et al.
patent: 6284757 (2001-09-01), Sanner
patent: 6521623 (2003-02-01), Cereda et al.
patent: 6586435 (2003-07-01), Cereda et al.
patent: 2003/0027823 (2003-02-01), Cereda et al.
patent: 2003/0060475 (2003-03-01), Borsini et al.
patent: 2003/0083228 (2003-05-01), Carpino et al.
patent: 2003/0104980 (2003-06-01), Borsini et al.
patent: 2003/0119850 (2003-06-01), Bombarda et al.
patent: 2004/0048877 (2004-03-01), Friedl et al.
patent: 2004/0180904 (2004-09-01), Beck
patent: 2004/0235861 (2004-11-01), Borsini et al.
patent: 2005/0065158 (2005-03-01), Naylor et al.
patent: 2005/0159430 (2005-07-01), Bombarda et al.
patent: 2005/0239798 (2005-10-01), Pyke
patent: 2005/0245539 (2005-11-01), Mendla et al.
patent: 2006/0014757 (2006-01-01), Pyke
patent: 2006/0025420 (2006-02-01), Brauns et al.
patent: 0200322 (1986-11-01), None
patent: 0 526 434 (1993-02-01), None
patent: 0 526 434 (1993-02-01), None
patent: 0705832 (1996-04-01), None
patent: 0816356 (1998-01-01), None
patent: 0982030 (2000-03-01), None
patent: 1256343 (2002-11-01), None
patent: 2023594 (1980-01-01), None
patent: WO 95/034555 (1995-12-01), None
patent: WO 98/42344 (1998-10-01), None
patent: WO 00/028993 (2000-05-01), None
patent: WO 01/021593 (2001-03-01), None
patent: WO 03/013539 (2003-02-01), None
patent: WO 03/035072 (2003-05-01), None
Boehringer Ingelheim (IT), Prop INN, 1,3-Dihydro-1-[2-[4-[3[(trifluoromethyl)phenyl]-1-piperazinyl]-22h-benzimidazol-2-one, Drugs of the Future, 1998, 23(1):9-16.
Cynthia Darlinton, Flibanserin, Current Opinion in CPNS Investigational Drugs, 1999 1(4):510-513.
Borsini, F. et al; “BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex”; Naunyn-Schmiedeberg's Archives of Pharm., 352(3), 1995 pp. 276-282.
Giron, D; “Thermal analysis and calorimetric methods in the characterisation of polymorphs and solvates”; Thermochimica ACTA, Elsevier Science; 248; 1995; pp. 1-59.
Bernstein, J. et al; “Concomitant Polymorphs”; Angewandte Chemie, Int. Ed., 1999, pp. 3441-3461.
Borsini, F., “Method of Using Flibanserin for Neuroprotection”; U.S. Appl. No. 10/214,781, filed Aug. 8, 2002.
Darlington, C.; “Flibanserin”, Current Opinion In CPNS Investigational Drugs; Bd 1 Nr. 4, 1999, pp. 510-513.
Borsini et al; Behavioral Effects of Flibanserin (BIMT 17), Sep. 1999, Pharmacology, Biochemistry and Behavior, vol. 64, Issue 1, see abstract.
Cools, A. R. “Depression and Psychosis” Behavioural Pharmacology of 5-HT, pp. 153-155 (1989).
Geyer, M. “5-HT2 antagonists increase tactile startle habituation in an animal model of habituation deficit in schizophrenia” Behavioural Pharmacology of 5-HT, pp. 243-246 (1989).
Bevan et al. “5-HT and Sexual Behaviour” Behavioural Pharmacology of 5-HT, pp. 33-34, 87-88 (1989).
Archer, T. “5HT, Pain and Anxiety” Behavioural Pharmacology of 5-HT, pp. 299-300 (1989).
Cloninger, C.R. “A Systematic Method for Clinical Description and Classification of Personality Variants” Arch. Gen. Psychiatry, vol. 44, pp. 573-588 (Jun. 1987).
Leonard, B. E. “Sub-types of serotonin receptors: biochemical changes and pharmacological consequences” International Clinical Psychopharmacology 7, 13-21 (1992).
Reikkinen et al. “The Effects of Increased Serotonergic and Decreased Cholinergic Activities on Spatial Navigation Performance in Rats” Pharmacology Biochemistry & Behavior, vol. 39, pp. 25-29 (1991).
Crook, T. and Lakin, M. “Effects of Ondansetron in Age-associated Memory Impairment” The role of ondansetron, a novel 5-HT3 antagonist, in the treatment of psychiatric disorders, 5th World Congress of Biochemical Psychiatry, pp. 21-23 (1991).
Jean L. Fourcroy “Female Sexual Dysfunction: Potential for Pharmacotherapy” Drugs 2003, vol. 63, No. 14, pp. 1445-1457.
Reuter, L. E. et al. “Electrophysiological examination of the effects of sustained flibanserin administration on serotonin receptors in rat brain” British J. of Pharm., 1999, vol. 126, No. 3, pp. 627-638.
Podhorna et al. “Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety” British J. of Pharm. 2000, vol. 130, No. 4, pp. 739-746.
Steiner, M. “Recognition of Premenstrual Dysphoric Disorder and Its Treatment” The Lancet, vol. 356, No. 9236, Sep. 30, 2000, pp. 1126-1127.
Dimmock, P. et al. “Efficacy of Selective Serotonin-Reuptake Inhibitors in Premenstrual Syndrome: A Systematic Review” The Lancet, vol. 356, No. 9236, Sep. 30, 2000, pp. 1131-1136.
Greene, T. “Protective Groups in Organic Synthesis”, Havard University, pp. 10-17, 1981 (Wiley-Interscience Publication).
Chemical Abstract: Database Accession No. 98:16650-XP 002197885 Collino, F. et al.: Mannich bases of benzimidazoles, benzotriazoles and other analogous compounds, with pharmacological activity.
Chalmers et al., “Corticotrophin-releasing factor receptors: from molecular biology to drug design”, TiPS vol. 17, pp. 166-172, Apr. 1996.
Lyrer, “Neue Ansatze in der Akutbehandlung des zerebrovaskularen Insultes” Schweiz. Med. Wochenschr., vol. 124, #45, 2005-2012 1994.
Frampton et al., Pentoxifylline (Oxpentiflline) A Review of its Therapeutic Efficacy in the Management of Peripheral Vascular and Cerebrovascular Disorders; (Drug Evaluation) Drugs and Aging 7(6), pp. 480-503, 1995.
Damour et al. CA 118-124537e (1992).
Awouters et al. CA 88-98788 (1977).
Vaudenberk et al. CA 88-50920n (1977).
Basson et al., “Report of the international consensus development conference on female sexual dysfunction: Definitions and Classifications”, The Journal of Urology; vol. 163; pp. 888-893: Mar. 2000.
Invernizzi et al., “Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT1Areceptors” British Journal of Pharmacology, vol. 139, pp. 1281-1288, Jun. 2003.
Bombarda Carlo
Dubini Enrica
Ezhaya Antoine
Schneider, legal representative Margarete
Bidachem S.p.A.
Devlin Mary-Ellen M.
Morris Michael P.
Nwaonicha Chukwuma
Page Thurman K.
LandOfFree
Stable polymorph of flibanserin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable polymorph of flibanserin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable polymorph of flibanserin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3862179